clonoSEQ

clonoSEQ

Medical and Diagnostic Laboratories

Seattle, Washington 376 followers

clonoSEQ® detects and tracks measurable residual disease (MRD) in lymphoid cancers to help inform patient care.

About us

Hundreds of academic and community centers use clonoSEQ® to track measurable residual disease (MRD). Why? Because with advanced treatments driving better outcomes, clonoSEQ has the sensitivity to deeply monitor those outcomes and inform patients’ next steps.1-5 Our customers choose to measure and monitor MRD with clonoSEQ because: • clonoSEQ is the most sensitive measure of MRD currently available2 • clonoSEQ is FDA-cleared and CLIA-validated* • clonoSEQ has national Medicare coverage† *clonoSEQ MRD test is FDA-cleared for B-ALL, CLL, and MM. clonoSEQ MRD test is CLIA-validated for DLBCL. †Medicare Advantage patients may have out-of-pocket costs for their unmet deductible or copays. Learn more about clonoSEQ by visiting https://www.clonoseq.com/about/. 1. Data on file. Adaptive Biotechnologies. 2022. 2. clonoSEQ®. [technical summary]. Seattle, WA: Adaptive Biotechnologies; 2020. 3. Lahuerta J, et al. J Clin Oncol. 2017;35(25):2900-2910. 4. Short N, et al. Am J Hematol. 2019;94:257-265. 5. Thompson P, et al. Leukemia. 2018;32(11):2388-2398.

Website
https://www.clonoseq.com/
Industry
Medical and Diagnostic Laboratories
Company size
501-1,000 employees
Headquarters
Seattle, Washington

Updates

Affiliated pages

Similar pages